• The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients. (nih.gov)
  • This nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. (nih.gov)
  • borderline resectable pancreatic cancer is defined as ≤90 degrees arterial and ≤ 270 degrees venous involvement without occlusion. (nih.gov)
  • The PREOPANC-2 trial directly compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer. (nih.gov)
  • Our study will provide evidence on the neoadjuvant treatment of choice for patients with resectable and borderline resectable pancreatic cancer. (nih.gov)
  • Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NAC-GA trial). (bvsalud.org)
  • The effectiveness of neoadjuvant therapy with nab- paclitaxel plus gemcitabine (GnP-NAT) in patients with borderline resectable pancreatic cancer (BRPC) remains unclear. (bvsalud.org)
  • The rationale for neoadjuvant chemoradiation therapy (Neo-CRT) and the definition of borderline resectable pancreatic cancer (BRPC) are still controversial. (elsevierpure.com)
  • Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). (springermedizin.at)
  • Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. (springermedizin.at)
  • To improve knowledge of current standards and future candidates of perioperative therapy to promote better outcome in patients with resectable NSCLC. (iaslc.org)
  • Patients with resectable stage I-IIIB NSCLC who underwent thoracic surgery from January 1, 2009, to December 31, 2018, from the Taiwan Cancer Registry were included. (appliedradiationoncology.com)
  • There was no improvement in a lower risk of death for patients with stage I-II NSCLC (after multivariable adjustment, the HR was 1.19 [95% CI: 0.89, 1.30], P = .65). (appliedradiationoncology.com)
  • Their results were in agreement with prior studies, likely due to the relatively low sensitivity and specificity of PET, which can result in false-negative results and miss occult cancer, especially in patients with early-stage NSCLC. (appliedradiationoncology.com)
  • The authors conclude, "The longer overall survival of the patients with stage IIIA-IIIB NSCLC in the preoperative PET/CT group can be attributed to a higher staging accuracy for advanced stages compared with those in the non-preoperative FDG PET/CT group. (appliedradiationoncology.com)
  • On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). (fda.gov)
  • Efficacy was evaluated in KEYNOTE-671 (NCT03425643), a multicenter, randomized, double-blind, placebo-controlled trial in 797 patients with previously untreated and resectable Stage II, IIIA, or IIIB (N2) NSCLC by AJCC 8th edition. (fda.gov)
  • Mark M. Awad, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings from the CheckMate 816 trial, which showed a potential clinical benefit to neoadjuvant nivolumab plus ipilimumab vs chemotherapy in patients with resectable non-small cell lung cancer (NSCLC) (Abstract 1261O). (ascopost.com)
  • Ze-rui Zhao, PhD, of China's Sun Yat-sen University Cancer Center, discusses new phase II findings on stereotactic body radiation therapy (SBRT) with sequential immunochemotherapy as a neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC). (ascopost.com)
  • Jonathan D. Spicer, MD, PhD, of McGill University, discusses findings from the KEYNOTE-671 study of perioperative pembrolizumab for patients with resectable early-stage non-small cell lung cancer (NSCLC). (ascopost.com)
  • Patients with treatment-naive resectable non-small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival a. (ascopost.com)
  • NADIM II confirms the superiority of neoadjuvant nivolumab plus chemotherapy in patients with resectable stage IIIA-B NSCLC," Provencio said, adding that it is "the first clinical trial with a neoadjuvant immunotherapy-based combination for resectable stage IIIA-B [NSCLC] to show improved overall survival. (medpagetoday.com)
  • It showed high survival rates , as well as better pCR, in patients with resectable stage IIIA NSCLC. (medpagetoday.com)
  • The phase III CheckMate 816 trial confirmed the findings of NADIM, showing improved event-free survival in patients and a high rate of pCR in patients with resectable stage IIIB NSCLC. (medpagetoday.com)
  • Research has shown that black patients diagnosed with early-stage NSCLC are less likely than white patients to undergo surgery and are more likely to undergo resection at low-volume hospitals and to die in the hospital or within 30 days of their operation. (onclive.com)
  • From the abstract: 'Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). (cdc.gov)
  • Background: Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. (elsevierpure.com)
  • The existing standard of care for patients with clinical stage III melanoma is upfront surgery and consideration for adjuvant therapy, which is insufficient to cure most patients. (elsevierpure.com)
  • Eligible participants were adult patients (aged ≥18 years) with histologically or cytologically confirmed surgically resectable clinical stage III or oligometastatic stage IV BRAF V600E or BRAF V600K (ie, Val600Glu or Val600Lys)-mutated melanoma. (elsevierpure.com)
  • Interpretation: Neoadjuvant plus adjuvant dabrafenib and trametinib significantly improved event-free survival versus standard of care in patients with high-risk, surgically resectable, clinical stage III-IV melanoma. (elsevierpure.com)
  • This program is designed to raise awareness and close knowledge gaps for medical oncologists, surgeons, dermatologists, oncology nurses, and oncology pharmacists regarding the expanding use of ICIs to treat patients with melanoma. (reachmd.com)
  • This activity is designed to meet the educational needs of medical oncologists, surgeons, dermatologists, oncology nurses, oncology pharmacists, and other members of the interprofessional team who are involved in the management of patients wit h melanoma. (reachmd.com)
  • Imlygic) was associated with a significant improvement in 5-year survival outcomes, including overall survival, compared with surgery alone in patients with advanced resectable melanoma , new data suggest. (medscape.com)
  • This phase 2, open-label randomized clinical trial enrolled 150 patients with resectable stage IIIB to IVM1a melanoma and one or more injectable cutaneous, subcutaneous, or nodal lesions. (medscape.com)
  • Neoadjuvant T-VEC May Improve Survival in Resectable Melanoma - Medscape - August 22, 2023. (medscape.com)
  • Neoadjuvant pembrolizumab therapy given to patients with stage III or IV resectable melanoma provides superior 2-year event-free survival in comparison to using only adjuvant therapy according to the findings of randomised, Phase II trial by US researchers. (hospitalhealthcare.com)
  • In a randomised, placebo-controlled trial of patients with completely resected stage III melanoma, adjuvant treatment with the programmed death 1 (PD-1) inhibitor, pembrolizumab, significantly improved recurrence-free survival compared to placebo . (hospitalhealthcare.com)
  • However, the added value of using neoadjuvant pembrolizumab therapy in patients with either stage III or IV resectable melanoma compared to adjuvant treatment alone has not been tested. (hospitalhealthcare.com)
  • In the current study, the US researchers undertook a randomised, Phase II, open-label trial, in patients with measurable stage IIIB to IVC melanoma that was amenable to surgical resection. (hospitalhealthcare.com)
  • Combination neoadjuvant immune checkpoint blockade therapy yielded promising outcomes in high-risk resectable melanoma, although toxicity was an issue, according to a phase II trial. (medpagetoday.com)
  • Patients were randomized to one of two 8- or 9-week immune checkpoint inhibitor regimens used in unresectable melanoma: PD-1 blockade with nivolumab 3 mg/kg -1 every 2 weeks or CTLA-4 blockade with ipilimumab 3 mg/kg -1 plus nivolumab 1 mg/kg -1 every 3 weeks. (medpagetoday.com)
  • The immune checkpoint inhibitor pembrolizumab achieved high response rates in patients with unresectable metastatic desmoplastic melanoma, a rare invasive tumor type, according to the results of the p. (ascopost.com)
  • Marcus O. Butler, MD, of Toronto's Princess Margaret Cancer Centre, discusses evidence of tumor response in orbital lesions treated with tebentafusp in patients with metastatic uveal melanoma. (ascopost.com)
  • However, the frequency of melanoma is increasing, particularly in lighter-skinned people, and for the minority of patients diagnosed with metastatic disease, the 5-year survival rate is 35%, although the introduction of immunotherapy has doubled the median survival time for these patients. (cdc.gov)
  • In this cohort study of 94 patients with resected melanoma brain metastases that underwent targeted DNA sequencing, BRAF V600E variant lesions were associated with worse intracranial progression-free survival and overall survival. (cdc.gov)
  • In this article, we review the data surrounding the use of chemotherapy (CT) and chemoradiotherapy (CRT) in patients with resectable pancreatic cancer. (cancernetwork.com)
  • Many oncologists advocate for adjuvant chemotherapy alone, given that high rates of systemic metastases are the primary cause of patient mortality. (cancernetwork.com)
  • Arrington AK, Nelson R, Patel SS, Luu C, Ko M, Garcia-Aguilar J, Kim J. Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. (wjgnet.com)
  • Patients with muscle loss >5% during neoadjuvant chemotherapy were less likely to undergo adjuvant chemotherapy than others (68% vs 85%, p = 0.048). (lu.se)
  • For medically fit patients, perioperative neoadjuvant chemotherapy or chemoradiotherapy followed by surgery is appropriate. (medscape.com)
  • [ 3 ] . For patients who received preoperative chemotherapy, the addition of postoperative radiotherapy has not demonstrated additional benefit. (medscape.com)
  • Medically unfit patients can be treated with chemoradiotherapy or chemotherapy. (medscape.com)
  • Improving the selection strategies can give patients a 5-year OS similar to other indications for LT and a better outcome than those undergoing chemotherapy alone. (unict.it)
  • Patients receive 8 cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3 cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36 Gy in 15 fractions) during the second cycle, followed by surgery and 4 cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. (nih.gov)
  • But this modality is reserved for patients who can tolerate this multicomponent chemotherapy regimen and may be limited in patients with significant comorbidities, including renal insufficiency. (jhoponline.com)
  • The patient received 3 cycles of chemotherapy and declined further treatment because of intolerable associated adverse events (including nausea, diarrhea, and fatigue). (jhoponline.com)
  • The use of chemotherapy in patients with cancer and renal impairment, especially in those with end-stage renal disease (ESRD), presents clinicians with multiple issues to consider. (jhoponline.com)
  • 7 A careful review of the literature and an evaluation of each agent's pharmacokinetics should be performed before the administration of chemotherapy in patients with ESRD. (jhoponline.com)
  • Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). (agmt.at)
  • The effect of Neo-CRT in BRPC with IVVI may be multifactorial, providing proper patient selection, complete adjuvant chemotherapy, and potential therapeutic (downstaging) effect. (elsevierpure.com)
  • By enabling accurate staging, diagnostic laparoscopy permits patient selection for curative resection or neoadjuvant chemotherapy while avoiding nontherapeutic laparotomy, which is associated with a delay in the initiation of chemotherapy. (medscape.com)
  • Patients were randomized (1:1) to either pembrolizumab or placebo, with platinum-based chemotherapy, every 3 weeks for 4 cycles (neoadjuvant treatment) followed by either continued single-agent pembrolizumab or placebo, every 3 weeks for up to 13 cycles (adjuvant treatment). (fda.gov)
  • This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. (cincinnatichildrens.org)
  • The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. (cincinnatichildrens.org)
  • It is not yet known whether high-dose combination chemotherapy and stem cell transplant are more effective than standard-dose combination chemotherapy in treating patients with refractory or relapsed germ cell tumors. (cincinnatichildrens.org)
  • On November 7, the U.S. Food and Drug Administration (FDA) revised the existing indication of pembrolizumab (Keytruda) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic. (ascopost.com)
  • Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in patients with early-stage triple-negative breast cancer, regardless of pathologic complete response (Abstract LBA18). (ascopost.com)
  • As reported in The Lancet Oncology by Sun Young Rha, MD, and colleagues, the phase III KEYNOTE-859 trial has shown that the addition of first-line pembrolizumab to chemotherapy was associated with a statistically significant improvement in overall survival in patients with HER2-negative advanced. (ascopost.com)
  • Hence, continued advancements in diagnostic techniques, chemotherapy and radiation therapy regimens, targeted therapy strategies, and cachexia treatments will be critical for improving patient outcomes ( Figure 1 ). (frontiersin.org)
  • A 2016 study found evidence that patients with stage 2 or stage 3 non-small cell lung cancer may benefit from induction chemotherapy before concurrent chemotherapy and radiation therapy. (healthline.com)
  • The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, accord. (ascopost.com)
  • Patients with un-resectable or borderline pancreatic cancer still have poor outcomes, with both toxicity and disease progression during induction chemotherapy limiting the number eligible for surgery. (moffitt.org)
  • GRECO-2 is a phase 2, multicenter, randomized, double-blind, placebo-controlled study to determine the effect on overall survival of adding GC4711 to SBRT following 4 months of chemotherapy in subjects with un-resectable or borderline non-metastatic pancreatic cancer. (moffitt.org)
  • In these patients who are poor candidates for resection, a combination of chemotherapy, locoregional therapies like ablation, transarterial chemo and radioembolization, and in very advanced and metastatic disease, external radiation are the available options. (mdpi.com)
  • VIENNA -- The addition of neoadjuvant nivolumab (Opdivo) to chemotherapy significantly improved outcomes in patients with resectable stage IIIA-B non-small cell lung cancer, according to results from the NADIM II trial. (medpagetoday.com)
  • The trial enrolled 90 patients from 20 academic centers across Spain, 86 of whom were randomized to a treatment arm: 57 to receive nivolumab/chemotherapy and 29 to chemotherapy alone. (medpagetoday.com)
  • Regarding surgery, 53 of the 57 patients in the nivolumab/chemotherapy arm (93%) underwent surgery compared with just 20 of 29 patients (69%) in the chemotherapy arm (OR 5.96, 95% CI 1.65-21.56). (medpagetoday.com)
  • In addition, the proportion of patients who had R0 surgery was higher in in the nivolumab/chemotherapy arm at 92.5% compared with 65% in the chemotherapy arm (OR 6.60, 95% CI 1.67-26.02). (medpagetoday.com)
  • And is there a risk that patients will have either no surgery or incomplete resections after chemotherapy/immunotherapy in the real world? (medpagetoday.com)
  • For example, with a predictive tool such as TA, physicians can tell patients to opt for treatment but inform them that they'd benefit more from up-front chemotherapy based on the TA results. (radiologytoday.net)
  • Even among patients who present with localized disease, the 5-year overall survival (OS) is approximately 20%, but potentially higher in patients with complete surgical resection (R0) and uninvolved lymph nodes. (cancernetwork.com)
  • All patients underwent curative resection of pancreatic adenocarcinoma without evidence of intraperitoneal disease. (cancernetwork.com)
  • Methods: Patients operated with liver resection for colorectal liver metastases between 2010 and 2014 were retrospectively reviewed. (lu.se)
  • more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). (nih.gov)
  • Methods: Cytological examination of peritoneal washings was performed in 134 patients who underwent surgical resection for pancreatic adenocarcinoma. (elsevierpure.com)
  • Resection remains the only cure for pancreatic cancer, which is available only to the minority of patients diagnosed at early stage. (jhoponline.com)
  • 1,2 Surgical resection remains the only cure for pancreatic cancer, which is only possible for patients with localized disease and without significant vascular involvement. (jhoponline.com)
  • 5 Neoadjuvant therapy is also recommended by the National Comprehensive Cancer Network (NCCN) for patients with high-risk clinical and laboratory features to promote successful resection. (jhoponline.com)
  • 5 According to a meta-analysis review of clinical trials examining the use of neoadjuvant FOLFIRINOX therapy for patients with pancreatic cancer, an estimated 68% of patients with borderline resectable disease will successfully undergo resection after 4 to 9 cycles of neoadjuvant FOLFIRINOX, with each cycle administered every 14 days. (jhoponline.com)
  • Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. (tokushima-u.ac.jp)
  • Two patients with progressive disease on monotherapy were unable to have definitive surgical resection after developing synchronous metastatic disease and local progression. (medpagetoday.com)
  • Patients with R0 resection confirmed by pathological evaluation initiated adjuvant administration of nivolumab within the third to eighth week from surgery and for 6 months. (medpagetoday.com)
  • Discussion: Single incision laparoscopic right hemicolectomy can be safely performed as an oncologic resection for patients who were candidates for conventional laparoscopic or hand-assisted partial colectomy. (sages.org)
  • METHODS: Eighty-four patients with resectable esophageal adenocarcinoma, who completed the planned preoperative chemoradiation and underwent a potentially curative esophageal resection were retrospectively evaluated. (who.int)
  • In such a patient, resection of an isolated adrenal metastasis has been demonstrated to extend disease-free survival. (medscape.com)
  • Forty-three patients were enrolled in this clinical trial comparing outcomes of surgery alone to CRT. (cancernetwork.com)
  • Patient characteristics including oncologic outcomes were analyzed for each of the 3 patients groups. (elsevierpure.com)
  • In this trial, randomization will be stratified by a modification of their IPFSG category and we will prospectively evaluate whether or not actual outcomes vary by risk group in the appropriate manner (low risk patients have higher OS than high-risk group). (cincinnatichildrens.org)
  • Neoadjuvant therapy involves the provision of systemic treatment before surgery and is designed to improve surgical outcomes for such patients. (hospitalhealthcare.com)
  • Moffitt was one of the high-volume centers with the last trial, which showed improved outcomes for these patients. (moffitt.org)
  • With texture imaging, physicians can assess outcomes by looking at thousands of images quantitatively, predicting who the better candidates for surgery are, and determining which therapy is best for each patient. (radiologytoday.net)
  • In this study, we investigated potential differences in clinical outcomes in esophageal adenocarcinoma patients based on the presence of identifiable Barrett's mucosa and/or history of symptomatic GERD. (who.int)
  • To describe the bleeding and thrombosis outcomes in hospitalised patients with confirmed COVID-19 receiving LMWH, with and without concomitant antiplatelet therapy. (bvsalud.org)
  • We conducted a descriptive, cross-sectional study of bleeding and thrombosis outcomes at Tygerberg Academic Hospital, Cape Town, South Africa, during the first COVID-19 wave, in 808 hospitalised patients with confirmed COVID-19 receiving LMWH with and without concomitant antiplatelet therapy. (bvsalud.org)
  • immunotherapy was associated with improved outcomes for patients with BRAF wildtype but not BRAF V600E variant brain metastases. (cdc.gov)
  • AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. (cancercentrum.se)
  • Most primary airway tumors are not resectable because of metastasis, locally advanced stage, or patient comorbidities. (msdmanuals.com)
  • [ 9 ] For example, an isolated ipsilateral adrenal metastasis in a patient with resectable, primary, non-small cell lung carcinoma is treated as localized disease. (medscape.com)
  • One patient , who had a history of radiation therapy for past esophageal cancer , died from exacerbation via pneumonia . (bvsalud.org)
  • This is a review of morbidity and mortality for first 51 MIE procedures for locally advanced esophageal cancer, that were resectable, on post neoadjuvant computerized tomography (CT) of chest and abdomen. (hindawi.com)
  • Patients were staged according to AJCC 7th edition classification for esophageal cancer. (hindawi.com)
  • Surgical removal remains the standard treatment for patients with early-stage esophageal cancer. (healthline.com)
  • NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). (springermedizin.at)
  • Results: Preoperative skeletal muscle mass was analysed in 225 patients, of whom 97 underwent. (lu.se)
  • In the matched cohort, 6754 patients (3349 men and 3405 women) underwent PET/CT and 6754 (3362 men and 3405 women) did not. (appliedradiationoncology.com)
  • In the absence of disease progression , patients underwent planned pancreatectomy . (bvsalud.org)
  • Patients with resectable disease then underwent minimally invasive esophagectomy (MIE). (hindawi.com)
  • Methods Retrospective single center cohort study of patients who underwent pancreaticoduodenectomy over the past 10 years for carcinoma obstructing the lower common bile duct. (thieme-connect.de)
  • Patients who underwent biliary stenting alone, biliary and pancreatic stenting, and no stenting prior to pancreaticoduodenectomy were the three study cohort groups and their records were scrutinized for the incidence of postoperative pancreatic fistula. (thieme-connect.de)
  • Results Sixty-two patients underwent biliary stenting alone, 5 patients underwent both biliary and pancreatic stenting, and 237 patients were not stented in the adenocarcinoma group without chronic pancreatitis. (thieme-connect.de)
  • The pancreatic fistula rate was similar in the patients who underwent biliary stenting alone when compared with the group which was not stented. (thieme-connect.de)
  • However, the patients who underwent both biliary and pancreatic stenting had a significant increase in postoperative pancreatic fistula compared with the not stented ( p = 0.003). (thieme-connect.de)
  • Methods: Between July 2009 and January 2010, 16 patients with the indication for a right hemicolectomy underwent a single incision laparoscopic approach without selection bias. (sages.org)
  • A study published in Radiology has found that the use of preoperative PET/CT is associated with lower risk of death in patients with stage IIIA-IIIB non-small cell lung cancer compared with those without preoperative PET/CT. (appliedradiationoncology.com)
  • Many agents are expected to be introduced into the perioperative treatment of resectable Stage IB to Stage III, but the balance of efficacy and adverse events varies for each subset of patients. (iaslc.org)
  • In using each agent in clinical practice, the debate continues as to whether a new perioperative therapy should be recommended for all patients or for a subset of patients. (iaslc.org)
  • Perioperative morbidity was in 16 (31.37%) patients. (hindawi.com)
  • Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. (cdc.gov)
  • A concern with any new adjuvant therapy is patients who progress after new adjuvant treatment, but also the proportion of patients who don't have surgery," commented Corinne Faivre-Finn, MD, PhD, of the University of Manchester, England, who served as study discussant at the WCLC session. (medpagetoday.com)
  • 1] Patients generally present with locally advanced or metastatic disease that precludes cure, since symptoms frequently prompt the diagnosis in the absence of effective screening strategies. (cancernetwork.com)
  • We focus in particular on primary resectable as well as advanced or metastatic disease. (springermedizin.at)
  • [ 3 ] Up to 27% of oncology patients will have microscopic adrenal metastases and approximately 50% of imaging-detected adrenal lesions in cancer patients will represent metastatic disease. (medscape.com)
  • Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1). (springermedizin.at)
  • This single- arm phase II trial included 61 patients with BRPC that were treated with two cycles of GnP-NAT, (nab- paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2), on days 1, 8, and 15 over a 4-week period, which comprised one cycle. (bvsalud.org)
  • On October 31, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) to be used with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. (ascopost.com)
  • Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. (medscape.com)
  • Pancreatic tumors that are considered to be borderline resectable may warrant neoadjuvant therapy to shrink the tumor for surgical intervention, with the goal of cure. (jhoponline.com)
  • In 73% of patients on combo therapy, tumors shrank and 45% of these patients had no evidence of disease at time of surgery. (medpagetoday.com)
  • The overall goal of this study is to develop Gallium Maltolate (GaM), an experimental drug, as a new oral treatment for patients with glioblastoma brain tumors whose tumor has relapsed after initial treatment or has progressed despite initial treatment. (froedtert.com)
  • The theme of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting is Partnering With Patients: The Cornerstone of Cancer Care and Research . (cancer.net)
  • Eligible patients were ≥ 18 years with histologically confirmed colorectal adenocarcinoma with liver-only or liver-dominant metastases, and treatment with LP-irinotecan TACE (LifePearl™ microspheres, Terumo Europe N.V., Leuven, Belgium) decided in a multi-disciplinary tumour board. (springer.com)
  • Abdel-Latif and colleagues recently suggested that esophageal adenocarcinoma patients with GERD might be resistant to multimodality treatment. (who.int)
  • The 5-year overall survival of patients with pancreatic cancer is approximately 5%, with potentially resectable disease representing the curable minority. (cancernetwork.com)
  • Overall, postoperative complications were found in 19 patients (42%) with 24 events, and nine patients (20%) with nine events ≥ grade IIIa, based on Dindo's classification . (bvsalud.org)
  • This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. (rush.edu)
  • All patients undergoing MIE at Shaukat khanum Memorial Cancer Hospital, for resectable esophageal cancers between January 2011 and May 2013, were reviewed. (hindawi.com)
  • Locally advanced or borderline resectable cancers continue to have a difficult prognosis. (moffitt.org)
  • The fibrinogen-platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. (tokushima-u.ac.jp)
  • Patients with locally advanced disease (patients with T3 or above and/or N1 disease) require neoadjuvant chemoradiotherapy prior to surgical intervention. (hindawi.com)
  • A population-based study on the management and outcome in patients with locally recurrent rectal cancer. (cancercentrum.se)
  • Treatment protocols for hepatocellular carcinoma are provided below, including those for patients with unresectable disease and patients with special considerations. (medscape.com)
  • Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. (medscape.com)
  • Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. (medscape.com)
  • Colorectal liver metastasises were once considered as incurable disease but with better treatment options and valuable input from multi-disciplinary teams, this disease can be cured in a proportion of patients. (wjgnet.com)
  • We randomly assigned patients (1:2) to either upfront surgery and consideration for adjuvant therapy (standard of care group) or neoadjuvant plus adjuvant dabrafenib and trametinib (8 weeks of neoadjuvant oral dabrafenib 150 mg twice per day and oral trametinib 2 mg per day followed by surgery, then up to 44 weeks of adjuvant dabrafenib plus trametinib starting 1 week after surgery for a total of 52 weeks of treatment). (elsevierpure.com)
  • Excluding one patient with atypical cells, positive cytology results were obtained in 19 patients (14 per cent): 16 patients without macroscopic peritoneal metastases (group 2) and three patients with minimal macroscopic peritoneal metastases (group 3). (elsevierpure.com)
  • Transarterial chemoembolisation (TACE) using irinotecan-eluting beads is an additional treatment option for colorectal cancer liver metastases (CRLM) patients that are not eligible for curative treatment approaches. (springer.com)
  • Transarterial chemoembolisation (TACE) using irinotecan-eluting beads is part of the loco-regional treatments toolbox to control colorectal cancer liver metastases (CRLM) in the 80% of patients that are not eligible for the only proven curative treatment options, surgery and thermal ablation [ 1 , 2 ]. (springer.com)
  • The potential for improved outcome in patients with hepatic metastases from colon cancer: A population-based study. (cancercentrum.se)
  • The tumor stage helps the doctor develop the best treatment plan for each patient. (cancer.net)
  • Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes. (rush.edu)
  • The advantage of a neoadjuvant approach in this setting is that it enables an interval evaluation of the tumor cells after therapy to determine the extent to which those tumor cells responded to the therapy in real time, and predict which patients are likely to experience durable responses going forward," co-author Michael Tetzlaff, MD, PhD, also of MD Anderson, said in a news release. (medpagetoday.com)
  • tumor-related pain) of patients treated with monotherapy but 73% (8/11) of patients treated with combo therapy. (medpagetoday.com)
  • Background: The aim of this study was to assess the implications of positive peritoneal washing cytology for management of patients with potentially resectable pancreatic cancer. (elsevierpure.com)
  • The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration. (facingourrisk.org)
  • A potentially higher risk of thrombosis in patients receiving LMWH and antiplatelet therapy was observed. (bvsalud.org)
  • Of the patients who received neoadjuvant treatment in the pembrolizumab arm, 6% were unable to receive surgery due to adverse reactions compared with 4.3% in the placebo arm. (fda.gov)
  • In addition, 3.1% of patients who received neoadjuvant treatment and surgery in the pembrolizumab arm had delays in surgery due to adverse reactions compared with 2.5% in the placebo arm. (fda.gov)
  • Hyperselected patients with liver-limited unresectable CLM, RAS and BRAF wild-type and curatively removed primary colon cancer are included. (unict.it)
  • Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. (medscape.com)
  • Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer. (tokushima-u.ac.jp)
  • This case report may serve as a guide for optimization of the FOLFIRINOX regimen in patients undergoing intermittent hemodialysis and provides recommendations for enhancing patient tolerability of this treatment. (jhoponline.com)
  • 802 patients were randomly assigned to receive durvalumab (400 patients) or placebo (402 patients). (cdc.gov)
  • RECIST overall response was documented in three of 12 patients on monotherapy versus eight of 11 patients on combo therapy. (medpagetoday.com)
  • 12 ] [ 13 ] [ 14 ] Although several meta-analyses and other retrospective studies have examined stented versus nonstented patients, they have not specifically addressed POPF rates. (thieme-connect.de)
  • New data show that patients treated for lung cancer at high safety-net burden hospitals undergo curative-intent surgery significantly less often than individuals treated at low safety-net burden facilities. (onclive.com)
  • Patients in the standard arm (surgery alone) will undergo large en- bloc curative intent surgery will be performed within 4 weeks following randomization. (who.int)
  • Despite these advances, there is a lack of biomarkers to inform us about the accurate management of the patients with metastatic CRC. (wjgnet.com)
  • The time is probably ripe for a clinical trial comparing a surgical to a non-surgical approach, with good integration of biomarkers for patient selection," she said. (medpagetoday.com)
  • In the CRT arm, there were issues of compliance, with 32% of patients assigned to CRT receiving inappropriate radiation and 25% of patients failing to initiate treatment within 10 weeks post surgery, the protocol-specified time limit. (cancernetwork.com)
  • However, many patients with pancreatic cancer do not receive surgery. (cancer.net)
  • Patients were randomly assigned to receive six doses of neoadjuvant T-VEC followed by surgery (group 1), or immediate surgery alone (group 2). (medscape.com)
  • Nevertheless, due to the advanced stage of the disease at the time of diagnosis, only a minority of patients are eligible for surgery. (frontiersin.org)
  • Results: Colon cancer and un-resectable polyps were the indication for surgery in all patients. (sages.org)
  • There's always debate among the treatment teams about which patients are better candidates for neoadjuvant therapy vs surgery first. (radiologytoday.net)
  • The authors said that more studies are needed to determine if the relationship between hospital safety-net burden and curative-intent surgery is the same for other cancer sites besides lung cancer, and whether safety-net burden is associated with receipt of multimodality therapy for patients with advanced disease. (onclive.com)
  • Approximately 10% to 15% of patients are diagnosed with this stage. (cancer.net)
  • Approximately 45% to 55% of patients are diagnosed with this stage. (cancer.net)
  • Patients were stratified by disease stage. (elsevierpure.com)
  • The inclusion of patients with stage IV oligometastatic disease was a study limitation, making the study participants "relatively heterogeneous," the authors noted, thereby decreasing the generalizability of the results to a stage III population. (medpagetoday.com)
  • Segelman J, Singnomklao T, Hellborg H, Martling A. Differences in MDT assessment and treatment between patients with stage IV colon and rectal cancer. (cancercentrum.se)
  • Further therapeutic advances and prospective trials are needed to better define the optimal role of adjuvant and neoadjuvant treatment in patients with resectable pancreatic cancer. (cancernetwork.com)
  • This protocol treatment is thought to be a feasible, safe, and promising treatment regimen, but we caution against its use in patients with a history of interstitial lung disease and/or prior pulmonary irradiation. (bvsalud.org)
  • To compare the treatments, the researchers monitored which patients did not need transfusions for at least 12 weeks and who had their levels of hemoglobin increase within the first 24 weeks of treatment. (cancer.net)
  • The U.S. Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor (CAR)-positive lymphoma, in patients who received treatment with B cell maturation antigen (BCMA)- or CD19-directed autologous CAR T-cell immunotherapies. (ascopost.com)
  • The researchers have designed a new 40-patient study, in collaboration with Memorial Sloan Kettering Cancer Center in New York City, to explore the safety and efficacy of neoadjuvant nivolumab plus the investigational treatment relatlimab, an inhibitor of the LAG-3 immune checkpoint. (medpagetoday.com)
  • Physicians and researchers work close together to provide innovative treatment options for patients. (moffitt.org)
  • We're very excited since pancreatic cancer continues to be such a difficult disease and we always want to expand treatment options for patients. (moffitt.org)
  • This interim analysis focuses on feasibility of the planned statistical analysis regarding data distribution and completeness, treatment intention, safety and health-related quality of life (HRQOL) of the first 50 patients prospectively enrolled in the CIrse REgistry for LifePearl™ microspheres (CIREL), an observational multicentre study conducted across Europe. (springer.com)
  • LP-irinotecan TACE was conducted in 42% of patients as salvage therapy, 20% as an intensification treatment, 16% as a first-line treatment, 14% a consolidation treatment and 8% combination treatment with ablation with curative intent. (springer.com)
  • So, with texture imaging, patients can be directed to a better treatment paradigm with more predictable tools. (radiologytoday.net)
  • However, there is scant information on the impact of hospital safety-net status on patient receipt of appropriate treatment. (onclive.com)
  • In total, 50 patients ≥ 18 years diagnosed with CRLM and decided to be treated with irinotecan-eluting LifePearl™ microspheres TACE (LP-irinotecan TACE) by a multidisciplinary tumour board. (springer.com)
  • The CIrse REgistry for LifePearl™ microspheres (CIREL) was designed to prospectively capture data of CRLM patients decided to be treated with TACE using irinotecan-eluting LifePearl™ microspheres (LP-irinotecan TACE). (springer.com)
  • The combination of ipilimumab and nivolumab may result in a higher levels of toxicities in patients with unresectable pleural mesothelioma than was reported in the CheckMate 743 trial, according to a recent study published by McNamee et al in the Journal of Thoracic Oncology. (ascopost.com)
  • Diagnostic laparoscopy is useful for making a definitive clinical diagnosis whenever there is a diagnostic dilemma even after routine diagnostic workup, including patients with nonspecific abdominal pain, hemodynamically stable patients who have sustained blunt or penetrating trauma with suspected intra-abdominal injuries, and critically ill intensive care unit (ICU) patients with suspected intra-abdominal sepsis or pathologies. (medscape.com)
  • Unfortunately, these approaches were often associated with prolonged hospital stays, higher numbers of radiologic imaging studies and laparotomies with negative findings, and patient dissatisfaction if the diagnosis could not be established. (medscape.com)
  • Regarding the utility of exploratory laparoscopy for patients with NSAP, a meta-analysis of four randomized control trials (N = 811) comparing exploratory laparoscopy with active observation concluded that early diagnostic laparoscopy was associated with a decreased number of patients discharged without a final diagnosis. (medscape.com)
  • NOTE: In rare circumstances, patients will be allowed to enroll even if a pathologic diagnosis may not have been established. (cincinnatichildrens.org)
  • Eligible patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1, a life expectancy of more than 3 years, and no previous exposure to BRAF or MEK inhibitors. (elsevierpure.com)
  • For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE's Project Facilitate at 240-402-0004 or email [email protected] . (fda.gov)
  • In a combined analysis of two Chinese phase II trials (RC48-C005 and RC48-C009) reported in the Journal of Clinical Oncology, Sheng et al found that the antibody-drug conjugate disitamab vedotin-an anti-HER2 antibody conjugated with monomethyl auristatin-produced promising results in patients with. (ascopost.com)
  • In the phase II TITAN-RCC trial reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy with or without nivolumab/ipilimumab as an immunotherapeutic boost was associated with activity in patients with metastatic clear cell renal cell carcinoma. (ascopost.com)